The Future of Medicine & Healthcare…
THE NEXT GREEN GOLD RUSH: MEDICAL MARIJUANA
A high-tech, climate-controlled medical marijuana greenhouse and prescription medicine.
By Les Hamasaki, Green Technology Editor
The Next Green Gold Rush is not only mining a new revenue source for financially stressed federal, state, and local governments, but also is about the future of medicine and healthcare. It is about finding a non-invasive natural cure for cancer and other degenerative diseases from plants like medicinal marijuana, or cannabis.
Wall Street investors are rushing to invest in growing medical marijuana in high-tech, climate-controlled, herbicide- and pesticide-free cleanroom greenhouses under natural and artificial light, with advanced oil-extracting technology for the production of cannabinoids. The goal is to find cures for over 60 types of diseases, as documented in U.S. Patent 6,630,507, issued on October 7, 2003*.
Dr. Raphael Mechoulam, an Israeli scientist and the father of medically oriented cannabis research, is the man responsible for identifying the chemical structures of both THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol), and discovering that our bodies have specific receptors for interacting with cannabis. Mechoulam also discovered the endocannabinoid system that affects every cell in the body, and determining that its manipulation could be instrumental in the treatment of a wide range of diseases. An overview of his lifetime work on cannabis is at www.zamnesia.com/blog–a–must–watch–medical–cannabis–documentary–the–scientistn757.
CNN journalist and neurosurgeon Dr. Sanjay Gupta stimulated a national dialogue on medical marijuana with three episodes of his series Weed (1, 2, 3). These episodes focused on the use of medical marijuana and its effect on children with epilepsy and veterans suffering from post-traumatic stress disorder (PTSD). These programs sparked a national debate on the efficacy of medical marijuana for curing cancer and reducing pain.
Currently, 23 states have legalized the use of cannabis for medical use and Colorado, Washington, Alaska, Oregon, and the District of Columbia have legalized it for recreational use. Soon California voters will decide on legalizing the recreational use of marijuana during the 2016 Presidential Election.
According to world-renowned medical cannabis research expert and author Robert J.
Melamede, Ph.D., “Modern, peer-reviewed science now clearly shows that all humans, and in fact all vertebrates, have an endocannabinoid system, meaning cannabis from within. Our endocannabinoid system regulates everything in our bodies from conception to death (circulatory, digestive, immune, nervous, reproductive, and tegumenary systems and musculature). Consequently, the medicinal value of cannabis is unique and incredibly powerful. I believe that as the cannabis awakening spreads across the world and the cannabinoid levels of the human population increase, we will benefit from a decrease in age-related illnesses (cancers and autoimmune, cardiovascular, neurological, and skeletal illnesses). Consequently, cannabis-based medicines that promote health will replace current pharmaceuticals — and their negative effects – in the treatment of many disorders. The big pharma approach to medicine will be replaced by more natural approaches that are more harmonious with life. The increase in cannabinoid activity will alter humanity’s dialogue with ourselves and with nature. It’s man’s greatest chance for surviving our natural stupid, greedy, and self destructive behavior that’s destroying the biosphere and its ability to support humans.”
The National Cancer Institute (NCI) of the National Institute of Health has updated the FAQs on its website to include recent studies on marijuana showing that it can and has killed cancer cells using animal studies.
These are the findings of some NCI cannabis studies:
- Cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow. Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells.
- Cannabinoids may protect against inflammation of the colon and may have potential in reducing the risk of colon cancer, and possibly in its treatment.
- A laboratory study of delta -9-THC in hepatocellular carcinoma (liver cancer) cells showed that it damaged or killed the cancer cells. The same study of delta-9THC in models of liver cancer showed that it had anti-tumor effects. Delta-9-THC has been shown to cause these effects by acting on molecules that may also be found in non-small lung cancer cells and breast cancer cells.
- A laboratory study of cannabidiol (CBD) in estrogen receptor-positive and estrogen receptor-negative breast cancer cells showed that it caused cancer cell death while having little effect on normal breast cells. Studies of metastatic breast cancer showed that cannabinoids may lessen the growth, number, and spread of tumors.
- A laboratory study of cannabidiol in human glioma cells showed that when given along with chemotherapy, CBD may make chemotherapy more effective and increase cancer cell death without harming normal cells. Studies showed that CBD together with delta-9-THC may make chemotherapy such as with temozolomide more effective.
These studies are considered by the NCI as pre-clinical. All were done using animals. According to NCI, no clinical trials of cannabis use for the treatment of cancer in humans have been published.
The NCI has included findings on peripheral benefits for cancer patients from marijuana:
- Delta-9-THC and other cannabinoids stimulate appetite and can increase food intake.
- Cannabinoid receptors have been studied in the brain, spinal cord, and nerve endings throughout the body to understand their roles in pain relief.
- Cannabinoids have been studied for anti-inflammatory effects that may play a role in pain relief.
The National Institute on Drug Abuse, another of the agencies of the National Institutes of Health, has referred to marijuana studies, including one that showed “marijuana can kill certain cancer cells and reduce the size of others.”
President Richard Nixon declared a “war on cancer” in 1975 – but still, today, one out of three women will contract breast cancer and one out of four men, over 65, will have prostate cancer. The only winners in the “war on cancer” are Big Pharma, Big Medicine, and Big Media thriving on a $1.2 trillion industry.
The “medical industrial complex” built and controlled by Big Pharma and Big Medicine and promoted by Big Media through television commercials are watching this unfolding drama that will have a major impact of their billion-dollar business model based on disease maintenance and management solutions that prescribe a “pill and bill for every ill” and “cut, burn and poison” with surgery, radiation, and chemotherapy, rather than a healthcare disease-prevention and wellness program that integrates natural medicine with exercise and plant-based nutrition. Hippocrates, the father of modern medicine, said, “Let food be thy medicine and medicine by thy food – and, above all, do no harm.”
Our federal, state, and many local governments are running up huge deficits, and therefore need to find new revenue sources. Congress is poised to legalize adult use of medical marijuana and tax cannabis at the federal level on top of the state and local levels, meaning the states wishing to legalize cannabis would no longer have to worry about intervention from the Federal level.
President Nixon’s declaration of the “war on drugs” over 44 years ago and listing of marijuana as a Schedule One drug, along with heroin and cocaine, resulted in many unintended consequences which American taxpayers are paying for now. The use of marijuana was decried by Big Media as a “gateway drug” that would lead to heroin and cocaine abuse and ultimately death; but government data showed there were more deaths caused by highly popular prescription drugs for pain and anxiety mixed with alcohol use than there were motor vehicle fatalities in 2009. There were at least 37,485 drug-related fatalities that year, according to preliminary data compiled by the U.S. Centers for Disease Control and Prevention. There were no reported statistics on the deaths due to marijuana abuse or overdose.”
Medical marijuana is one of many natural, inexpensive and disruptive healing solutions that will reinvent our broken and expensive healthcare system and impact Big Pharma’s control of the lucrative $1.2 trillion prescription drug market. It’s time for the federal government to chart a new course to legalize, regulate, and tax marijuana, much like alcohol and tobacco. The prohibition of marijuana has cost U.S. taxpayers billions of dollars not only in securing the U.S.-Mexico border, but also incarcerating an enormous number of young people, especially young male blacks and Latinos for minor drug infractions.
The “war on drugs” has destroyed our neighborhoods by giving the street gangs the financial power to spread nationally and internationally with easy drug money. Just as the prohibition of alcohol gave rise to the Mafia cartel with liquor during the 1920s, the “war on drugs” gave rise to the neighborhood street gangs in the ‘70s.
Nearly twenty years after voters made California the first state to legalize the use of medical marijuana, Governor Jerry Brown signed the most comprehensive bill to regulate the multibillion dollar business from “seed to sale” to generate revenue for the state and local governments. When California legalizes recreational marijuana use, the state can anticipate another multi-billion dollar revenue source.
President Obama and Congress along with local policy makers and leaders must rethink, revise, and reverse the current path along which the country seeks the health and wellness of its people by addressing the root causes of the diseases that affect our people, rather than the symptoms. The unintended consequences that result from our failed policies are a wake-up call for all Americans to rethink our national priorities in terms of our health, our safety, and our security.
Like solar and wind energy that accelerated the first green gold rush to assuring our energy independence and security from imported oil and creating a heathier environment, the Next Green Gold Rush: Medical Marijuana hopefully will empower people to live a healthier and pain-free lifestyle without invasive surgery, radiation, or chemotherapy. This vision is a big part of the future of medicine, promising to lead us to change our healthcare system from remediation and damage control to prevention and wellness for generations to follow.
Les Hamasaki is a sustainable development urban planner and former Los Angeles City Planning Commissioner under Mayor Richard Riordan and Los Angeles Airport Commissioner under Mayor Tom Bradley. He is the Executive Director of the JW Kennedy Foundation, Inc., an integrative naturopathic non-profit corporation.
RESPONSE FROM THE ALZHEIMER’S ASSOCIATION TO “THE NEXT GREEN GOLD RUSH: MEDICAL MARIJUANA….THE FUTURE OF MEDICINE AND HEALTHCARE.”
Thanks for contacting the Alzheimer’s Association. In recent years, there have been several studies focusing on the potential role of cannabinoids in fighting Alzheimer’s disease, Parkinson’s disease, and related dementias. Cannabinoids are the active chemicals in marijuana. The Alzheimer’s Association is currently funding a research project that aims to determine whether cannabinoid drugs can protect dementia-related brain cell damage in mice. The abstract for this project, which appears on
“TDP43 (TAR DNA binding protein-43) is a protein linked to several brain diseases. Abnormal forms of TDP43 are found in people who have Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (Lou Gehrig’s disease) and frontotemporal dementia. Each of these conditions is characterized by inflammation and degeneration of nerve cells.
Using mice genetically altered to have abnormal TDP43, the researchers plan to determine if this genetic change causes alterations in the endocannabinoid system. The endocannabinoid system refers to the ability of some nerve cells in the brain to respond to a class of drugs known as cannabinoids. Cannabinoids can come from external sources (such as cannabis) or from naturally occurring molecules in the brain (endocannabinoids). Several studies have shown that activation of the endocannabinoid system in the brain can reduce inflammation and potentially reduce damage to nerve cells.
Eva De Lago, Ph.D. and colleagues have proposed to study if drugs activating the endocannabinoid system can protect against nerve cell damage in animals with abnormal TDP43. They will then study whether cannabinoid drugs protect the brain from damage related to abnormal TDP43. These studies will help to determine whether cannabinoids may be worth further study for slowing or preventing progression of Alzheimer’s disease and several related conditions.”
Another research effort is reviewing several studies on the therapeutic potential of cannabinoids in brain disease. The abstract for this project appears at http://www.ncbi.nlm.nih.gov/pubmed/23829360. It states:
“The endocannabinoid system (ECS) is now recognized as an important modulator of various central nervous system processes. More recently, an increasing body of evidence has accumulated to suggest antioxidant, anti-inflammatory and neuroprotective roles of ECS. In this review we discuss the role and therapeutic potential of ECS in neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease, multiple sclerosis, Huntington’s disease, Tourette’s syndrome, brain ischemia and amyotrophic lateral sclerosis (ALS). Elements of the ECS, such as fatty acid amide hydrolase or the cannabinoid receptors are now considered as promising pharmacological targets for some diseases. Although still preliminary, recent reports suggest that modulation of the ECS may constitute a novel approach for the treatment of AD.”
Lastly, I’ve included below the abstract from a third research effort on the endocannabinoid system. This study, also funded by the Alzheimer’s Association, focuses on how endocannabinoids may affect cell-to-cell communication in the brain.
Keep in mind, however, that all of these studies are at a preliminary stage of development. It will be some time before we truly understand the possible links between marijuana and Alzheimer’s disease …. and before marijuana (or the active chemicals in marijuana) can be considered an appropriate Alzheimer’s therapy.
I hope you find this information helpful.
Deficits in Anandamide Signaling Underlie Cognitive Dysfunction in Alzheimer’s Disease
Kwang Mook Jung, Ph.D.
University of California, Irvine
Investigator-Initiated Research Grant
Endocannabinoids are naturally occurring brain chemicals similar to the active ingredient in marijuana. Research indicates that these chemicals can protect brain cells from injury and degeneration. Endocannabinoids may also affect the function of synapses, the tiny channels through which brain cells send and receive chemical messages. These findings suggest that alterations in the endocannabinoid system may inhibit the ability of brain cells to communicate with one another.
In previous research with autopsied brain tissue, Kwang Mook Jung, Ph.D., and colleagues found significantly less anandamine, a type of endocannabinoid, in the brains of people with Alzheimer’s disease than in healthy brains.
For this grant, the researchers hope to confirm their earlier result. They also plan to examine whether alterations in the endocannabinoid system affect levels of beta-amyloid in the brain. Beta-amyloid, a protein fragment, is a key suspect in Alzheimer’s disease. This fragment is suspected of damaging synapses and disrupting cell-to-cell communication within the Alzheimer brain. Using cultured neurons, Dr. Jung’s team will test whether an increase in betaamyloid levels decreases the number of endocannabinoids. They will also test whether amyloidinduced damage to synapses is associated with disruptions in the endocannabinoid system.
Results of Dr. Jung’s research could lead to lead to new therapeutic strategies for preventing and treating Alzheimer’s disease.
On Sat, Oct 24, 2015 at 8:40 AM, ALZ Info <[email protected]> wrote:
The email below was received at the [email protected] mailbox. We would appreciate it if you would reply to the email. If you are not the best person or department to respond to the email, please let us know. It is our goal to answer all emails within 1 business day.
The Contact Center Email Team
RESPONSE BY WENDY COLEMAN ON TOWER GARDENS TO GROW YOUR OWN MEDICINE
RESPONSE FROM JOHN WAYNE KENNEDY
We need an intergraded approach to all diseases.
The various associations must also take a close look at the technology that utilizes ionic minerals including Zinc, Copper and Magnesium since the combinations attack all abnormal cells and tissue while preserving the healthy adjoining tissues.
The J W Kennedy Foundation does not have the funding to support the research to fund programs such as that on ALS and cancer but have encouraging results.
We can support your efforts in your research with our data and understanding of the mechanisms and our success in the treatment of other diseases.
We are attaching a informal explanation of the mechanism of the science and will welcome your comments. Please direct your response to Les Hamasaki for distribution.
John Wayne Kennedy
Bioavailable Ionic Minerals for Disease Mitigation Abstract
John W. Kennedy, July 3, 2014
The Cancer Cell (CC) Formula is an experimental treatment which is currently being researched on cancer, infectious and other diseases. This technology targets cells which do not follow the Krebs metabolic cycle by delivering a lethal dose of minerals (zinc and copper) to those cells. Because cancer cells follow an anaerobic, non-Krebs metabolism, it is predicted to target cancer cells precisely. Normal, healthy cells which follow the Krebs cycle should absorb the minerals that they need and reject the rest. Because bacteria and fungi follow non-Krebs metabolic cycles, the product may also be capable of treating a variety of infections. The formulation uses highly bioavailable cations through inorganic coordination complexes formed by the coordinate bond formation between an electropositive mineral cation and molecular groups that pose unshared electron pairs. A salicylic acid preparation can enhance transport of free zinc and copper ions systemically through tissue via an artificial superoxide dismutase (SOD) radical.
A topical version has been tested on over 100 volunteer subjects during eight years of informal trials on a variety of diseases. Results reported have been extremely positive. Cancer patients using the topical formulation reported that dead cancer cells were excreted by the body via the skin, stool, or urine. Although many experienced pain and other effects, subjects reported that the effects ended upon conclusion of the treatment. The treatment has also been tested on MRSA and ALS patients with promising results. The product is currently undergoing additional pre-clinical doctor-supervised case studies on several types of diseases.
Abstract ………………………………………………………………………………………………………………………….. 1
The Science ……………………………………………………………………………………………………………………… 2
Mode of Action ………………………………………………………………………………………………………………… 7
Appendix 1 – Treatment Protocol ………………………………………………………………………………………. 10
Appendix 2 – Information for Test Subjects ………………………………………………………………………… 12
Appendix 3 – Background of Inventor ………………………………………………………………………………… 19
References ……………………………………………………………………………………………………………………. 20
The Krebs cycle, also known as the citric acid cycle or the tricarboxylic acid cycle (TCA cycle), describes the metabolic pathways of the higher-order plants and animals in which available fuels, oxygen, water, and other essentials to life are utilized in an aerobic mode. The metabolic system is a well-documented and familiar process involving the basic steps to produce a “higher” form of life. The protection provided by at least 32 steps in the process provides a system that protects the oxygen-driven plants and animals.
Lower-order organisms are not near as complex in their metabolic pathways as higher-order organisms such as a tree or a human. The cycle followed by organisms such as bacteria and fungi, as well as certain diseased cells in higher-order life forms, follow a less complicated process that allows the disease to multiply at an almost exponential rate in an anaerobic cycle that has far fewer steps. The unique metabolic cycle of cancer cells and their ravenous appetite was first observed by Warburg1. The disease utilizes all available minerals, sugars, fats, and proteins to fuel the reproduction of cells using the abbreviated anaerobic cycle. The higher the rate of replication, the less oxygen is available for healthy tissues surrounding the disease. Reduced oxygen aids in the fermentation process that is part of the favorable conditions required for the exponential growth of cells and organisms employing the anaerobic cycle, including infections and abnormal cells.
The CC Formula exploits a flaw in the exponential expansion mechanism of the disease organism. Specifically, it exploits the mineral-gathering mechanism of the organism against itself2. Lower orders of disease organisms gather the necessary minerals and other building blocks in an amount proportional to their availability in the environment. This differs from the metabolic processes of higher organisms that only gather enough of the elements and building blocks to satisfy the requirements of the Krebs cycle.
Higher organisms will only incorporate minerals and other nutrients at a rate necessary for survival, while lower organisms and certain diseased cells will accumulate minerals in an amount that is toxic. Therefore, providing a high concentration of ionic minerals to a disease area could result in a toxic level of the mineral to disease organisms and allow survival of higher organisms so long as the dosage rate of the ionic minerals is below the toxic level for the higher organism.
The CC Formula uses highly bio-available ionic minerals at a rate that will kill the lower organism without impairing the function of the higher organism. This formulation transports all ~ the minerals systemically to a plant, animal, or human with assistance of an artificial superoxide dismutase (SOD) carrier. The artificial SOD carrier causes the disease-causing cell or organism to uptake an amount of ionic mineral that is toxic which results in death of the disease cell or organism. Additionally, many diseases follow an anaerobic fermentation process which oxygen will impair thereby suggesting a secondary mechanism for destroying the disease. The CC Formula also contains sulfur which may further aid in destroying disease and relief of pain. However, the prime mode of action is the uptake of minerals in a highly biologically available formulation.
The general principle of the CC Formula is rapid entry into the aerobic biological system of a plant or animal using a mineral complex carrier in an ionic form which penetrates and migrates toward an anaerobic disease system if present. The product is capable of penetrating the barrier zone between the aerobic and anaerobic tissues if the disease is internal. Other mineral formulations are not as bioavailable, being unable to pass through cellular tissues as easily as the CC Formula. The unique quality of the formulation is thus its penetration of the membrane and the movement of large amounts of ionic minerals into the disease area.
Diseases have three vulnerable sites that can be attacked by treatment:
- Penetrating the outer membrane of the disease,
- Destroying the internal components that drive the cells metabolism, and
- Destroying the gene pool that may provide a future defense (resistance) against the introduced substance.
Minerals that are not in the bioavailable form will not be able to eliminate or otherwise disable the disease cells because the minerals cannot pass through the membrane coating the outer surface of the disease cells and/or cannot travel in an extracellular fashion. The bioavailable minerals will attack all of the vulnerable targets in the disease cells because of the systemic capabilities of the formulation. When using the bioavailable formulation, the cell membrane should be easily transversed and possibly ruptured, the inner cell compromised because of the Krebs cycle (aerobic vs. anaerobic) as described above, and the genetic code of the disease cell destroyed by apoptosis. There should be no further deviations from the genetic code to produce new strains that may be resistant to the CC Formula. In fact, there are no known resistances to plant and/or animal disease when the primary source of the product being used is a mineral.
Complex Ion Formation of Mineral Complex Bonds
The complex ions and inorganic coordination complexes are formed by the coordinate bond formation between an electropositive mineral cation (positive) and molecular groups that possesses unshared electron pairs (ammonia). Every metal ion has at least one coordination sphere which determines the number of coordinate bonds possible for each mineral atom. The coordinate bonds attract negatively charged ions possessing unshared electron pairs. All cations except those in periodic table Groups IA and IIA exist as complex cations with a definite number of coordinating groups bound to them. The cations use the unshared pair in attempting to fill gaps in the outer electron orbitals where those electron shells are incomplete. The bonds formed between the cation and the unshared pair of electrons are mineral complex bonds. An exemplary compound can be produced as a result of the acid-base reaction when sulfuric acid is combined with ammonia sulfate is ammonia (NH3). Ammonia is one of the compounds having an unshared pair of electrons that enables mineral complex bond formation between itself and the free cation in solution. The nitrogen atom includes an unshared pair of electrons. Ammonia is very reactive in mineral complex bonding due to its respectively small size, and the unshared pair of electrons. The two hydrogen atoms cannot equalize the charge due to repulsion between the electron pair making ammonia polar. Therefore, for example, ammonia may enter into the following two complexes:
- Cu+2 (Copper ion) + 4NH3→[Cu(NH3)4]+2
- Zn+2 (Zinc ion) + 4NH3→[Zn(NH3)4]+2
The number of ammonia molecules is double the metallic ion valence, and the valence charge does not change. The unshared pair of electrons forms the mineral complex bonds, the complex system supplying both the unshared electrons. The resulting compound is a plurality of ammonia molecules bonded to a single molecule of ionic mineral forming an encapsulated mineral surrounded by ammonia “mineral complex bonds.” This molecular diagram is shown for purpose of example only and the zinc cation may be substituted by any of the cation ions. This compound, including ammonia encapsulating a bioactive mineral cation, is hereinafter referred to as a “mineral complex system.” Additionally, urea may be included in the formulation resulting in mineral complex bonding of the cations with the urea. In this composition, the bioavailable minerals could be formulated with the urea producing a cream containing higher than anticipated mineral content than is normally expected in the formulations.
Examples of the mineral complex compounds are:
As another example, in aqueous solutions without complexing agents, cobalt+2 is the favored state. In the presence of complexing agents such as ammonia, NH3, complexes of cobalt+3 have greater stability and are more stable in basic media than acid media. Additionally, compound bonding is conducive to maintain the abundance of hydrogen ions. The resulting solution has a very low pH reading (at or near zero) because of the combined bonded mineral ions. The CC Formula does not act as a conventional acid because of the stability of the mixture. The pH of the products is not indicative of the expected acid characteristics one might imagine at a pH of 1.0 or below. The solution can only be reduced by non-heat evaporation to a certain volume. The efficiency of the CC Formula is in direct relation to the amount of free zinc ions. The complex ion and/or inorganic coordination complexes using zinc is prepared by combining and agitating zinc sulfate (ZnSO4) with a mixture of ammonium hydrogen sulfate (NH4HSO4) and water. The result is a zinc mineral complex system that has the ability to penetrate through cell membranes without being blocked. The complex has a strong positive charge and is readily accepted into the cell.
Other products containing zinc only produce a limited amount of ionic zinc. Zinc oxide, for example, releases zinc ions depending on the acidity of the product. Zinc sulphate has a weaker bonding structure than does zinc oxide. It generates complex cations and inorganic coordination complexes which allow the ions to act independently without a counter-balance at a cell membrane and can be translocated throughout the body, passing through healthy cells with no effect. Without being processed properly, zinc sulphate will be rejected at the cell membrane and only a small amount of zinc ions will enter the cell, making this method highly ineffective. The CC Formula uses zinc and copper in a 7:2 ratio. This active ingredient complex can be mixed in a topic cream base which does not interfere with the acidity of the product. Other means of delivering the active ingredients are being researched.
Secondary Active Complex
The formulation includes a high level of sulfur which functions as a secondary active complex. This complex can operate synergistically with the mineral complex by accelerating the treatment of the affected cells. The high level of free sulfur can be transported to various locations and may speed reconstitution of damaged tissue affected by the disease. Sulfur is a non-metallic acidic macromineral usually consumed as part of a larger compound (zinc, copper, etc.) and is not usually expressed as an aid to the mitigation of disease. However, the benefits of sulfur are well known and the formulation that combines a high-sulfur content (NH4HSO4) base with the minerals with radicals that contain sulfur (zinc sulfate, etc.) will provide an abundance of free sulfur that may accumulate in those regions of the human body that require attention. The preferred mineral radical would be a sulfate for that reason but is not necessary for the success of the free sulfur. The benefits of sulfur include boosting the immune system and providing pain relief to targeted cells. The mechanism by which free sulfur produced in this mixture operate similarly to the operative mode of glucosamine sulfate, chondroitin sulfate, and methylsulfonylmethane (MSM).
Superoxide Dismutase (SOD)
Superoxide dismutases (SOD) are essential enzymes that eliminate superoxide radical (O2-) and thus protect cells from damage induced by free radicals. The active O2– production and low SOD activity in cancer cells may render the malignant cells highly dependent on SOD for survival and sensitive to inhibition of SOD.
The CC Formula also contains a mineral complex of ammonia ligands in combination with the zinc and copper forming a Super Oxide Dismutase (SOD) that is a highly effective antiinflammatory agent and has strong antiviral properties. SOD is an oxygen scavenger that may be effective in renewing tissue damaged by disease, mechanical damage such as cuts, and may even be effective against radiation damage by the Sun. Our artificial SOD has a relatively low molecular weight compared to natural SODs, which should increase its bioavailability.
A deficiency of cytochrome oxidase is a metabolic defect of cancer cells that causes a blockage of cellular respiration or oxidative energy production. Bioavailable copper and a SOD make copper and zinc available to the cytochrome oxide enzyme that is copper dependent. The process can be exemplified by the use of salicylic acid in the formulation and produce an effect similar to the use of an aspirin to relieve pain where the salicylate combines with the available copper and that residing in the stomach lining and transported to the site of the pain. The CC Formula, with its bioavailable Cu/Zn SOD, counteracts the effects of overproduction of superoxide by utilizing a mineral complex system which can permeate into the affected tissues and countering of the overproduction of superoxide. A Cu/Zn superoxide dismutase (SOD) is used that neutralizes the debilitating effects suffered by individuals that are producing excessive superoxide causing the symptoms of neural disorders, suggesting that its effects on ALS3 and similar diseases. A patent addressing that particular disease has been submitted. SOD is also known as an anti-inflammatory treatment for traumas it is considered over 3000 times stronger than vitamin C as a nutrient. Thus a key attribute of the CC Formula is not only its ionic minerals but its SOD, both highly bioavailable.
Mode of Action
As described above, the CC Formula uses ionic mineral complexes that are predicted to be capable of penetrating tissue, benefitting normal cells, and destroying diseased or mutant cells. A Superoxide Dismutase (SOD) carrier provides for extracellular transport of the ionic minerals systemically throughout the region of topical application. The method of action on disease described herein stems from both the scientific theory (section above) and test results (section below).
The ionic mineral complexes are believed capable of penetrating cell membranes at a rapid pace. The formulation thus may present highly bioavailable minerals to cells. The minerals should be blocked from excess absorption by normal cells following the Krebs cycle, which will not allow entry of an abnormally high concentration of minerals. Instead, the excess minerals should travel through the cells without disrupting normal cell functions. Cells which do not follow the Krebs cycle do not have the regulatory capabilities of the Krebs cycle. These non-normal cells receive an overload of minerals, resulting in mineral toxicity. The process of destruction of the diseased and other non-normal cells is in some cases may be aided by the added effect of oxidation of the anaerobic disease fermentation process. Once the targeted cells die, testing has observed that the body’s natural capabilities expel the dead cells through the skin, urine, or feces.
Another mode of action is the effect of the ionic mineral complex on bacteria or other pathogens or saprophytic organisms that surround and act to encapsulate a disease region such as a tumor. Tumors are typically surrounded by a sheath containing the disease (including cancer), immune system cells, bacteria, viruses, and/or other organisms. High numbers of bacteria, etc. have been identified in the protective membrane and may be responsible for the membrane’s existence. The bioavailable ionic mineral complexes in the CC Formula are predicted to have antimicrobial properties and be able to freely move among and through cells. These complexes may thus be capable of reaching the interface between the healthy and diseased tissues and destroying the organisms that exist in the protective membrane.
Cancer is typically not recognized as a threat by the immune system of the body. The composition exposes the cancer as a foreign body to the immune system which attacks the cancer, activates the immune response, and causing the body to destroy the cancer and/or expel and/or absorb the cancer. Additionally, in animals without an immune system, the composition will not be able to promote immune response. However, the formulation may have cytotoxic effects that may kill the cancer in immune-resistant hosts.
We believe that building a strong immune system to fight off diseases and an immune system that is challenged by disease will improve effectiveness of the CC Formula. It is important that ~ the proper vitamin, minerals and other support directed at building an immune response be pursued. We also believe that the use of botanicals will support the treatment via use of complementary modes of action.
In summary, when the mineral complex system is introduced into a cell, we predict that the minerals will dissociate from the complex and be highly bioavailable to the cell. These minerals are predicted to kill the cancer, bacteria, and fungi cells through the different modes of action causing degradation of the growth and death of the cancer cells, much like antibodies do to any foreign body during an immune response. Other aids to building the immune response and botanicals can be of assistance in treating the diseases.
The CC Treatment is considered experimental and has not undergone formal clinical trials. However, there have been extensive informal tests by volunteers on the treatment, as described below. Formal testing on the treatment has been limited. The topical formulation has undergone successful skin irritation testing4 and is currently being laboratory tested against a number of pathogens. The product is also currently being tested by doctors in case studies in several countries as a form of pre-clinical trials on a number of diseases such as skin cancer and MRSA. One physician plans to test an injectable formulation, which might allow a higher rate of effects on internal tumors than is achieved via topical application.
Based on the results of these pre-clinical case studies, it is expected that the topical formulation may enter clinical trials for targeted diseases. Other limited-claim pathways to early markets, such as a disinfectant, are being explored.
The CC formula has gone through years of development, starting with various animals over eight years ago. Over the
years of testing and reformulation, numerous informal human studies have shown remarkable successes. The diversity of these case studies is summarized below.
Breast Cancer 4
Colon Cancer 1
Ovarian Cancer 2
Brain Tumor 2
Stomach Cancer 1
Prostate Cancer 1
Lung Cancer 2
Throat Cancer 1
Skin Ulcers 3
Skin Infections 15
Fungal Infections 3
Dental Infection 3
Testicular Cancer 1